myodine
le vet beheer -
deca durabolin 50 mg/ml raztopina za injiciranje
raztopina za injiciranje - nandrolon
deca durabolin 50 mg/ml raztopina za injiciranje
raztopina za injiciranje - nandrolon
dantrolen i.v. 20 mg prašek za raztopino za infundiranje
sanolabor, d.d. - prašek za raztopino za injiciranje - dantrolen
dantrolen i.v. 20 mg prašek za raztopino za injiciranje
kemofarmacija d.d. - prašek za raztopino za injiciranje - dantrolen
dantrolen i.v. prašek za raztopino za injiciranje
lenis d.o.o. - prašek za raztopino za injiciranje - dantrolen
dantrolen i.v. 20 mg prašek za raztopino za injiciranje
lenis d.o.o. - prašek za raztopino za injiciranje - dantrolen
dantrium intravenous
lenis d.o.o. - natrijev dantrolenat - prašek za raztopino za injiciranje - natrijev dantrolenat 20 mg / 1 viala - dantrolen
abiraterone accord
accord healthcare s.l.u. - abirateron acetat - prostatične neoplazme - endokrini terapija - abiraterone accord is indicated with prednisone or prednisolone for:the treatment of newly diagnosed high risk metastatic hormone sensitive prostate cancer (mhspc) in adult men in combination with androgen deprivation therapy (adt)the treatment of metastatic castration resistant prostate cancer (mcrpc) in adult men who are asymptomatic or mildly symptomatic after failure of androgen deprivation therapy in whom chemotherapy is not yet clinically indicatedthe treatment of mcrpc in adult men whose disease has progressed on or after a docetaxel based chemotherapy regimen.
abiraterone mylan
mylan ireland limited - abirateron acetat - prostatične neoplazme - endocrine therapy, other hormone antagonists and related agents - abiraterone mylan is indicated with prednisone or prednisolone for:the treatment of newly diagnosed high risk metastatic hormone sensitive prostate cancer (mhspc) in adult men in combination with androgen deprivation therapy (adt). the treatment of metastatic castration resistant prostate cancer (mcrpc) in adult men who are asymptomatic or mildly symptomatic after failure of androgen deprivation therapy in whom chemotherapy is not yet clinically indicated. the treatment of mcrpc in adult men whose disease has progressed on or after a docetaxel based chemotherapy regimen.